Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al.. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347

The Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA.
Nature Medicine (Impact Factor: 27.36). 04/2006; 12(3):342-7. DOI: 10.1038/nm1358
Source: PubMed


We have previously shown that a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B. We carried out a phase 1/2 dose-escalation clinical study to extend this approach to humans with severe hemophilia B. rAAV-2 vector expressing human F.IX was infused through the hepatic artery into seven subjects. The data show that: (i) vector infusion at doses up to 2 x 10(12) vg/kg was not associated with acute or long-lasting toxicity; (ii) therapeutic levels of F.IX were achieved at the highest dose tested; (iii) duration of expression at therapeutic levels was limited to a period of approximately 8 weeks; (iv) a gradual decline in F.IX was accompanied by a transient asymptomatic elevation of liver transaminases that resolved without treatment. Further studies suggested that destruction of transduced hepatocytes by cell-mediated immunity targeting antigens of the AAV capsid caused both the decline in F.IX and the transient transaminitis. We conclude that rAAV-2 vectors can transduce human hepatocytes in vivo to result in therapeutically relevant levels of F.IX, but that future studies in humans may require immunomodulation to achieve long-term expression.

Download full-text


Available from: Margareth Ozelo, Mar 06, 2015
  • Source
    • "A human codon-optimized acid a-glucosidase cDNA (coGAA) (GeneArt; Life Technologies) was cloned into a desmin promoter construct (pTR-DES) previously described (Pacak et al., 2009; Falk et al., 2013). The liver-specific promoter (LSP) (GeneArt; Life Technologies) contains the apolipoprotein E-hepatocyte control region (Miao et al., 2000; Manno et al., 2006; Cao et al., 2007), the human a 1 -antitrypsin promoter (Cresawn et al., 2005), and 5¢ untranslated region (UTR) and was subcloned into pTR-DES-coGAA in lieu of the DES promoter (BglII and SalI). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Limiting factors in large pre-clinical and clinical studies utilizing adeno-associated virus (AAV) for gene therapy are focused on the restrictive packaging capacity, the overall yields and the versatility of the production methods for single AAV vector production. Furthermore, applications where multiple vectors are needed to provide long expression cassettes, whether due to long cDNA sequences or the need of different regulatory elements, require that each vector be packaged and characterized separately, directly affecting labor and cost associated with such manufacturing strategies. To overcome these limitations, we propose a novel method of vector production that allows for the packaging of multiple expression cassettes in a single transfection step. Here we combined two expression cassettes in predetermined ratios prior to transfection and empirically demonstrate that the output vector recapitulates the predicted ratios. Titration by quantitative PCR (qPCR) of AAV vector genome copies using shared or unique genetic elements allowed for delineation of the individual vector contribution to the total preparation which showed the predicted differential packaging outcomes. By co-packaging GFP and mCherry constructs, we demonstrate that both vector genome and infectious titers reiterated the ratios utilized to produce the constructs by transfection. Co-packaged therapeutic constructs that only differ in transcriptional elements produced a heterogeneous vector population of both constructs in the predefined ratios. This study shows feasibility and reproducibility of a method that allows for two constructs, differing in either transgene or transcription elements, to be efficiently co-packaged and characterized simultaneously, reducing cost of manufacturing and release testing.
    Full-text · Article · Aug 2014 · Human Gene Therapy Methods
  • Source
    • "Although there is no direct evidence that intracellular processing and presentation of AAV onto MHC I differ among serotypes, anecdotal evidence supporting this hypothesis comes, for example, from the observation that the administration of AAV2 and AAV8 vectors to the liver of humans at similar doses results in different kinetics of activation cytotoxic T cell immunity against the transduced hepatocytes (9, 60, 74). Whether these differences can be ascribed to the vector serotype only is unknown, as in vitro studies comparing AAV serotypes have been challenging due to differences in efficiency of AAV transduction among serotypes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene therapy and, recently, to the market approval of an AAV-based drug in Europe. With clinical development, however, it became obvious that the host immune system represents an important obstacle to successful gene transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxic T cell responses directed against the AAV capsid encountered on human studies. While over the past several years the field has acquired a tremendous amount of information on the interactions of AAV vectors with the immune system, a lot of questions are still unanswered. Novel concepts are emerging, such as the relationship between the total capsid dose and the T cell-mediated clearance of transduced cells, the potential role of innate immunity in vector immunogenicity highlighted in preclinical studies, and the cross talk between regulatory and effector T cells in the determination of the outcome of gene transfer. There is still a lot to learn about immune responses in AAV gene transfer, for example, it is not well understood what are the determinants of the kinetics of activation of T cells in response to vector administration, why not all subjects develop detrimental T cell responses following gene transfer, and whether the intervention strategies currently in use to block T cell-mediated clearance of transduced cells will be safe and effective for all gene therapy indications. Results from novel preclinical models and clinical studies will help to address these points and to reach the important goal of developing safe and effective gene therapy protocols to treat human diseases.
    Full-text · Article · Jul 2014 · Frontiers in Immunology
  • Source
    • "Unfortunately, the lack of immunity in pre-clinical studies did not fully reflect clinical results. In patient studies using AAV2 or AAV8 expressing normal or self-complimentary (sc) hFIX respectively, AAV1 expressing α1-antityrpsin (AAT), and Lipoprotein Lipase (LPL) correction, capsid-specific CTL responses have emerged, particularly at high doses (8–11). In some cases, existence of capsid-specific CTLs did not significantly impact correction as seen in AAT studies involving intramuscular (IM) injections (10). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transitioning to human trials from preclinical models resulted in the emergence of inhibitory AAV vector immune responses which has become a hurdle for sustained correction. Early animal studies did not predict the full range of host immunity to the AAV vector in human studies. While pre-existing antibody titers against AAV vectors has been a lingering concern, cytotoxic T-cell (CTL) responses against the input capsid can prevent long-term therapy in humans. These discoveries spawned more thorough profiling of immune response to rAAV in pre-clinical models, which have assessed both innate and adaptive immunity, and explored methods for bypassing these responses. Many efforts towards measuring innate immunity have utilized Toll-Like Receptor (TLR) deficient models and have focused on differential responses to viral capsid and genome. From adaptive studies, it is clear that humoral responses are relevant for initial vector transduction efficiency while cellular responses impact long-term outcomes of gene transfer. Measuring humoral responses to AAV vectors has utilized in vitro neutralizing antibody (NAb) assays and transfer of seropositive serum to immunodeficient mice. Overcoming antibodies using CD20 inhibitors, plasmapheresis, altering route of delivery and using different capsids have been explored. CTL responses were measured using in vitro and in vivo models. In in vitro assays expansion of antigen-specific T cells as well as cytotoxicity towards AAV transduced cells can be shown. Many groups have successfully mimicked antigen-specific T cell proliferation, but actual transgene level reduction and parameters of cytotoxicity towards transduced target cells has only been shown in one model. The model utilized adoptive transfer of capsid specific in vitro expanded T-cells isolated from immunized mice with LPS as an adjuvant. Finally, the development of immune tolerance to AAV vectors by enriching regulatory T-cells has also been explored as well as modulating t
    Full-text · Article · Feb 2014 · Frontiers in Immunology
Show more